ARC Group Featured in The Smart Investor’s Exclusive September-October 2024 Edition

ARC Group Featured in The Smart Investor’s Exclusive September-October 2024 Edition

ARC Group, a leading global advisory firm, has been prominently featured in the September-October 2024 edition of The Smart Investor. Known for its expertise in Special Purpose Acquisition Companies (SPACs), ARC Group has successfully facilitated over 50 SPAC listings on major U.S. stock exchanges, including the New York Stock Exchange and NASDAQ, cementing its position as a leader in the SPAC market.

In this special feature, Paul Chong, Venture Partner at ARC Group, outlines the significant benefits of pursuing an Initial Public Offering (IPO) in the U.S. With over $7 billion in completed SPAC transactions, he has been a central figure in driving SPAC activity, particularly across the Asian market. He emphasizes how the U.S. offers unparalleled advantages for international companies, including access to the world’s largest and most liquid capital markets, superior valuations, and the prestige associated with being listed on globally renowned exchanges.

The Smart Investor SPAC article

Additionally, Paul highlights the ease of follow-on equity offerings, credible institutional equity research, and the vast network of global investors that U.S. IPOs attract, offering companies significant growth potential. With lower thresholds for listing and the availability of U.S.-dollar denominated acquisition capital, ARC Group continues to help companies from Asia and beyond tap into these opportunities, positioning themselves for future success. Read the full article here (subscription required).

Ready to talk to one of our experts?

Contact us here for all your capital markets and M&A needs.

Not quite ready for an IPO yet? Our consulting division is here to help you prepare for the future. Get in touch to explore how we can support your growth journey.

For media inquiries, please contact:

Anna Sahlberg Carlsson
Marketing Manager
[email protected]

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission